List view / Grid view
23 April 2014 | By AbbVie
AbbVie announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50th Annual Meeting of the American Society of Clinical Oncology...
23 April 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
23 April 2014 | By Biogen Idec
Biogen Idec Inc. reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013...
22 April 2014 | By Enterome
ENTEROME bioscience SA is pleased to announce that Prof. Alessandra Cervino has joined the Company as Head of Discovery...
22 April 2014 | By Novartis
Novartis announced that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio...
22 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses...
17 April 2014 | By The European Medicines Agency
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin (trastuzumab), thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries...
17 April 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the US Food and Drug Administration and the European Commission have granted volasertib* ‘orphan drug designation' for the treatment of patients with acute myeloid leukaemia...
16 April 2014 | By Janssen
Additional analyses presented in European and hepatitis C genotype 4 patient subgroups underscore benefit of simeprevir-based treatment regimens...
16 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the US Food and Drug Administration has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes...
15 April 2014 | By Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting…
15 April 2014 | By AbbVie
AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib...
15 April 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year...
Abbott announced today that its new ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test – which can aid physicians in diagnosing and monitoring diabetes and identifying people at risk for the disease – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). More than 25 million Americans are…
